Eric Lu

1.0k total citations
19 papers, 298 citations indexed

About

Eric Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Eric Lu has authored 19 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Eric Lu's work include Cancer Immunotherapy and Biomarkers (4 papers), Sarcoma Diagnosis and Treatment (3 papers) and Renal cell carcinoma treatment (2 papers). Eric Lu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Sarcoma Diagnosis and Treatment (3 papers) and Renal cell carcinoma treatment (2 papers). Eric Lu collaborates with scholars based in United States, Taiwan and Greece. Eric Lu's co-authors include Ko‐Hsiu Lu, Chiao‐Wen Lin, Shun‐Fa Yang, Jia‐Sin Yang, Joseph J. Shatzel, Thomas G. DeLoughery, Jose Rueda, Sven R. Olson, Chih‐Hsin Tang and Yi‐Hsien Hsieh and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Pharmacology & Therapeutics.

In The Last Decade

Eric Lu

17 papers receiving 297 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Lu United States 10 129 62 55 54 51 19 298
Yan Qi China 11 173 1.3× 26 0.4× 33 0.6× 62 1.1× 83 1.6× 26 361
Chaozhe Yang United States 11 446 3.5× 29 0.5× 24 0.4× 162 3.0× 26 0.5× 15 608
Kelly Koral United States 10 109 0.8× 29 0.5× 25 0.5× 46 0.9× 26 0.5× 15 325
Zhigang Nie China 8 182 1.4× 53 0.9× 77 1.4× 78 1.4× 35 0.7× 9 349
Lang Liu China 12 219 1.7× 82 1.3× 159 2.9× 40 0.7× 33 0.6× 33 370
Bingqiang Gao China 10 137 1.1× 78 1.3× 52 0.9× 69 1.3× 64 1.3× 21 401
Xiaonan Qiu China 13 210 1.6× 37 0.6× 122 2.2× 32 0.6× 72 1.4× 34 403
Qianwei Xiong China 10 145 1.1× 49 0.8× 68 1.2× 25 0.5× 26 0.5× 24 279

Countries citing papers authored by Eric Lu

Since Specialization
Citations

This map shows the geographic impact of Eric Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Lu more than expected).

Fields of papers citing papers by Eric Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Lu. The network helps show where Eric Lu may publish in the future.

Co-authorship network of co-authors of Eric Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Lu. A scholar is included among the top collaborators of Eric Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Lu. Eric Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Shatila, Malek, Sidra Naz, Eric Lu, et al.. (2025). Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events. Targeted Oncology. 20(2). 329–337.
2.
Lu, Eric, Malek Shatila, Anusha Shirwaikar Thomas, et al.. (2024). The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity. American Journal of Clinical Oncology. 48(3). 136–141. 1 indexed citations
3.
Shatila, Malek, et al.. (2024). S3844 Atypical Presentations of Immune Checkpoint Inhibitor Colitis on 18-FDG PET/CT: A Case Series. The American Journal of Gastroenterology. 119(10S). S2514–S2514.
4.
Lu, Ko‐Hsiu, et al.. (2023). Curcumin and its Analogs and Carriers: Potential Therapeutic Strategies for Human Osteosarcoma. International Journal of Biological Sciences. 19(4). 1241–1265. 39 indexed citations
5.
Lu, Ko‐Hsiu, et al.. (2023). Different molecular weights of hyaluronan research in knee osteoarthritis: A state-of-the-art review. Matrix Biology. 117. 46–71. 25 indexed citations
6.
Lu, Eric, Paul C. Boutros, Liying Zhang, et al.. (2023). Fumarate Hydratase Variants and Their Association With Paraganglioma/Pheochromocytoma. Urology. 176. 106–114. 6 indexed citations
7.
Makrakis, Dimitrios, Scott J. Dawsey, Tyler F. Stewart, et al.. (2022). Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology. 40(6_suppl). 505–505. 1 indexed citations
8.
Lu, Eric, Kathryn E. Hatchell, Sarah M. Nielsen, et al.. (2021). Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. Cancer. 128(4). 675–684. 16 indexed citations
9.
Lu, Ko‐Hsiu, Eric Lu, Chih‐Hsin Tang, et al.. (2021). The potential remedy of melatonin on osteoarthritis. Journal of Pineal Research. 71(3). e12762–e12762. 29 indexed citations
10.
Lu, Ko‐Hsiu, Jia‐Sin Yang, Yi‐Hsien Hsieh, et al.. (2021). Lipocalin-2 Inhibits Osteosarcoma Cell Metastasis by Suppressing MET Expression via the MEK–ERK Pathway. Cancers. 13(13). 3181–3181. 16 indexed citations
11.
Yang, Jia‐Sin, et al.. (2021). GO-Y078, a Curcumin Analog, Induces Both Apoptotic Pathways in Human Osteosarcoma Cells via Activation of JNK and p38 Signaling. Pharmaceuticals. 14(6). 497–497. 16 indexed citations
12.
Abel, Melissa L., et al.. (2020). The Evolving Landscape of Antibody–Drug Conjugates for Urothelial Carcinoma. Clinical Genitourinary Cancer. 19(3). 183–193. 9 indexed citations
13.
Lu, Ko‐Hsiu, et al.. (2020). New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacology & Therapeutics. 214. 107611–107611. 63 indexed citations
14.
15.
16.
Lu, Eric, George Thomas, Yiyi Chen, et al.. (2018). DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of the National Comprehensive Cancer Network. 16(8). 933–937. 8 indexed citations
17.
Olson, Sven R., et al.. (2018). When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. American Journal of Nephrology. 48(2). 96–107. 41 indexed citations
18.
Lu, Eric, James B. Hayden, Arthur Hung, et al.. (2018). Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas. Annals of Surgical Oncology. 25(4). 920–927. 8 indexed citations
19.
Lu, Eric, et al.. (2017). What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature. Seminars in Oncology. 44(1). 8–12. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yan Qi Breakdown of academic impact, for papers by Chaozhe Yang Breakdown of academic impact, for papers by Kelly Koral Breakdown of academic impact, for papers by Zhigang Nie Breakdown of academic impact, for papers by Lang Liu Breakdown of academic impact, for papers by Bingqiang Gao Breakdown of academic impact, for papers by Xiaonan Qiu Breakdown of academic impact, for papers by Qianwei Xiong
Rankless by CCL
2026